Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Fuchs, R; Schraml, E; Leitinger, G; Stelzer, I; Allard, N; Haas, HS; Schauenstein, K; Sadjak, A.
á1-Adrenergic drugs modulate differentiation and cell death of human erythroleukemia cells through non adrenergic mechanism.
Exp Cell Res. 2011; 317(16):2239-2251
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Fuchs Robert
Haas Helga Susanne
Leitinger Gerd
Meier-Allard Nathalie
Sadjak Anton
Schauenstein Konrad
Schraml Elisabeth
Stelzer Ingeborg
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Preliminary data showed that á1-adrenergic antagonists induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells. To test the hypothesis whether survival and differentiation of erythroleukemia cells are under control of á1-adrenergic signalling, we examined á1-adrenoceptor expression of erythroleukemia cells and compared the in vitro effects of á-adrenergic antagonists with those of agonists. We discovered that á1-adrenergic agonists suppress both erythroid differentiation and growth of erythroleukemia cells concomitant with lipofuscin accumulation, autophagy and necrotic cell death. á1-adrenergic agonists also inhibit the in vitro growth of physiologic hematopoietic progenitors obtained from umbilical cord blood with high selectivity for the erythroid lineage. Interestingly, the observed effects could not be related to á1-adrenoceptors, even though agonists and antagonists displayed opposing effects regarding cellular growth and differentiation of erythroleukemia cells. Our data suggest that the effects of á1-adrenergic drugs are related to a non-adrenoceptor binding site, controlling the fate of erythroid progenitor cells towards differentiation and cell death. Since the observed effects are not mediated through adrenoceptors, the physiologic relevance of our data remains unclear, so far. Nevertheless, the identification of the still unknown binding site(s) might disclose new insights into regulation of erythroid differentiation and cell death. Copyright © 2011 Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Adrenergic alpha-1 Receptor Agonists - pharmacology
Adrenergic alpha-Agonists - pharmacology
Adrenergic alpha-Antagonists - pharmacology
Antigens, CD45 - metabolism
Apoptosis - drug effects
Autophagy - drug effects
Caspase 3 - metabolism
Cell Aggregation - drug effects
Cell Death - drug effects
Cell Differentiation - drug effects
Cell Line, Tumor -
Cell Proliferation - drug effects
Cell Survival - drug effects
Drug Interactions -
Erythroid Cells - cytology
Erythroid Precursor Cells - cytology
Fetal Blood - cytology
Gene Expression - drug effects
Glycophorin - metabolism
Hemin - pharmacology
Hemoglobins - metabolism
Humans -
Hydrogen-Ion Concentration - drug effects
K562 Cells -
Leukemia, Erythroblastic, Acute - metabolism
Megakaryocyte Progenitor Cells - cytology
Megakaryocytes - cytology
Naphazoline - pharmacology
Necrosis - chemically induced
Oxathiins - pharmacology
Prazosin - pharmacology
Receptors, Adrenergic, alpha-1 - genetics

Find related publications in this database (Keywords)
Erythroleukemia cells
Erythroid progenitor cells
alpha 1-adrenergic drugs
Cell death
Differentiation
© Meduni Graz Impressum